Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials
The DOI matches its Crossref record; 33 of the 34 references it cites were found in a registry or an index; none of the 25 sources its claims cite is checked for support yet.
Abstract
Background In early breast cancer, variations in local treatment that substantially affect the risk of locoregional recurrence could also affect long-term breast cancer mortality. To examine this relationship, collaborative meta-analyses were undertaken, based on individual patient data, of the relevant randomised trials that began by 1995. Methods Information was available on 42,000 women in 78 randomised treatment comparisons (radiotherapy vs no radiotherapy, 23,500; more vs less surgery, 9300; more surgery vs radiotherapy, 9300). 24 types of local treatment comparison were identified. To help relate the effect on local (ie, locoregional) recurrence to that on breast cancer mortality, these were grouped according to whether or not the 5-year local recurrence risk exceeded 10% ( 10%, 25,000 women). Findings About three-quarters of the eventual local recurrence risk occurred during the first 5 years. In the comparisons that involved little ( 10%) differences, however, 5-year local recurrence risks were 7% active versus 26% control (absolute reduction 19%), and 15-year breast cancer mortality risks were 44.6% versus 49.5% (absolute reduction 5.0%, SE 0.8, 2p Interpretation In these trials, avoidance of a local recurrence in the conserved breast after BCS and avoidance of a local recurrence elsewhere (eg, the chest wall or regional nodes) after mastectomy were of comparable relevance to 15-year breast cancer mortality. Differences in local treatment that substantially affect lo…
Overview
CoChat Summary
## TL;DR
This EBCTCG individual-patient-data overview of randomized trials in early breast cancer found that larger reductions in 5-year local recurrence were associated with larger reductions in 15-year breast cancer mortality. The main pattern was consistent across radiotherapy after breast-conserving surgery and after mastectomy with axillary clearance, while older radiotherapy regimens also showed excess contralateral breast cancer and non-breast-cancer mortality.
## Key findings
- Across 78 randomized treatment comparisons involving about 42,000 women, 24 local-treatment comparisons were grouped by 5-year local recurrence reduction; in comparisons with substantial differences, 5-year local recurrence was 7% with active treatment vs 26% with control and 15-year breast cancer mortality was 44.6% vs 49.5% (absolute reduction 5.0%, SE 0.8, 2p < 0.00001).
- In the 10 trials of radiotherapy after breast-conserving surgery (BCS), radiotherapy reduced local recurrence by about 70% overall (recurrence rate ratio about 0.3), and the 15-year breast cancer death rate ratio was 0.83 (95% CI 0.75–0.91, 2p = 0.0002), corresponding to 30.5% vs 35.9% at 15 years.
- In the 25 trials of radiotherapy after mastectomy and axillary clearance, node-negative women had 5-year local recurrence 6% without RT vs 2% with RT and no significant 15-year breast cancer mortality reduction, whereas node-positive women had 23% vs 6% local recurrence and 54.7% vs 60.1% 15-year breast cancer mortality (absolute reduction 5.4%, SE 1.3, 2p = 0.0002).
- The paper reports that for local-treatment differences reducing 5-year local recurrence by 20%, the corresponding estimated reduction in 15-year breast cancer mortality was 5.2% (SE 0.8, 2p < 0.00001), and that about three-quarters of eventual local recurrence risk occurred in the first 5 years.
## Methods
- Collaborative meta-analyses of individual patient data from randomized trials of local treatment in early breast cancer that began by 1995, updated from earlier EBCTCG reviews.
- Data were available on about 42,000 women in 78 randomized treatment comparisons: radiotherapy vs no radiotherapy, more vs less surgery, and more surgery vs radiotherapy; analyses were grouped by whether 5-year local recurrence risk differed by <10% or >10%.
- Main analyses were stratified by trial, time since randomisation, and nodal status, with some analyses also stratified by age; local recurrence, breast cancer mortality, and overall mortality were the principal outcomes.
## Limitations
- The paper states that overall tests of heterogeneity with many degrees of freedom are not very sensitive to real heterogeneity if it exists.
- It notes that the report does not investigate how more modern radiotherapy and surgery techniques might avoid the long-term fatal or nonfatal adverse effects seen with some older regimens.
- Evident from the text: some subgroup and site-specific results are based on small numbers or incomplete information (for example, local-recurrence site was “not generally available” in post-mastectomy trials, and several tables note missing or unavailable data).
Model-written summary of a shortened version of the paper’s full text (it is longer than we read). Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 0 Not valid · 7 Not checked · 94 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the comparisons that involved little ( < 10%) difference in 5-year local recurrence risk there was little difference in 15-year breast cancer mortality.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“15-year breast cancer mortality risks 54·7% versus 60·1% (reduction 5·4%, SE 1·3, 2p=0·0002”
plainstates a causen = 8,500 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“overall mortality reduction 5·3%, SE 1·8, 2p=0·005”
plainstates a causen = 7,300 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Among the 25 000 women in the comparisons that involved substantial ( > 10%) differences, however, 5-year local recurrence risks were 7% active versus 26% control (absolute reduction 19%)”
plainstates a causen = 25,000- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“15-year breast cancer mortality risks 30·5% versus 35·9% (reduction 5·4%, SE 1·7, 2p=0·0002”
- Also stated in: § Radiotherapy after BCS · plain
“The 15-year risk of death from breast cancer (in the hypothetical absence of other causes) is 30·5% among those allocated post-BCS radiotherapy and 35·9% among those not (corresponding to an absolute reduction of 5·4%, SE 1·7)”
plainstates a causen = 7,300 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Radiotherapy after BCS · plain
66 more claims
Create a free account to see all 101 claims and to verify the 25 references still open.
- The quote only partly states this claim. 6
- It may state two separate claims as one. 24
- Probably not a substantial claim. 5
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Breast-conserving surgery combined with radiation therapy is standard treatment for early stage breast cancer and provides equivalent survival to mastectomy [20-27].”
From Is the breast-conserving treatment with radiotherapy appropriate in BRCA1/2 mutation carriers? Long-term results and review of the literature (2010) · cites this paper as [27]
Citations
Cites
Fisher, B., Anderson, S., Bryant, J., Margolese, R. G., Deutsch, M., Fisher, E. R., Jeong, J.-H., & Wolmark, N. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa022152 · Cited by 6,249
Overgaard, M., Hansen, P. S., Overgaard, J., Rose, C., Andersson, M., Bach, F., Kjaer, M., Gadeberg, C. C., Mouridsen, H. T., Jensen, M.-B., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710023371401 · Cited by 2,554
Adjuvant Radiotherapy and Chemotherapy in Node-Positive Premenopausal Women with Breast Cancer
Ragaz, J., Jackson, S. M., Le, N., Plenderleith, I. H., Spinelli, J. J., Basco, V. E., Wilson, K. S., Knowling, M. A., Coppin, C. M. L., Paradis, M., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710023371402 · Cited by 1,745
Overgaard, M., Jensen, M.-B., Overgaard, J., Hansen, P. S., Rose, C., Andersson, M., Kamby, C., Kjaer, M., Gadeberg, C. C., Rasmussen, B. B., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(98)09201-0 · Cited by 1,602
Darby, S. C., McGale, P., Taylor, C. W., & Peto, R. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70251-5 · Cited by 1,049
Ragaz, J., Olivotto, I. A., Spinelli, J. J., Phillips, N., Jackson, S. M., Wilson, K. S., Knowling, M. A., Coppin, C. M. L., Weir, L., Gelmon, K., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh297 · Cited by 1,027
Effects of Radiotherapy and Surgery in Early Breast Cancer — An Overview of the Randomized Trials
(1995) · New England Journal of Medicine · doi:10.1056/nejm199511303332202 · Cited by 1,012
Bartelink, H., Horiot, J.-C., Poortmans, P., Struikmans, H., Van den Bogaert, W., Barillot, I., Fourquet, A., Borger, J., Jager, J., Hoogenraad, W., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010874 · Cited by 941
Cited by
(2011) · The Lancet · doi:10.1016/s0140-6736(11)61629-2 · Cited by 3,937
Self-citationRisk of Ischemic Heart Disease in Women after Radiotherapy for Breast Cancer
Darby, S. C., Ewertz, M., McGale, P., Bennet, A. M., Blom-Goldman, U., Brønnum, D., Correa, C., Cutter, D., Gagliardi, G., Gigante, B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209825 · Cited by 3,974
Giuliano, A. E. (2011) · JAMA · doi:10.1001/jama.2011.90 · Cited by 2,942
Liedtke, C., Mazouni, C., Hess, K. R., André, F., Tordai, A., Mejia, J. A., Symmans, W. F., Gonzalez-Angulo, A. M., Hennessy, B., Green, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.4147 · Cited by 2,892
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Aebi, S., Davidson, T., Gruber, G., & Castiglione, M. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq159 · Cited by 2,842
Metadata
- Authors
- Clarke, M. J.
- Affiliations
- University of Oxford (GB)
- Corresponding author
- Mike J Clarke
- ORCID
- Mike J Clarke
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2005-12
- Volume
- 366
- Issue
- 9503
- Pages
- 2087-2106
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2158615473
- Semantic Scholar
- 35d12770a704178c15468cf3695f81703a3a2a6e
- Cited by
- 5,127
- References
- 34
- Citations by year
- 2026: 78 · 2025: 111 · 2024: 161 · 2023: 191 · 2022: 205 · 2021: 233 · 2020: 230 · 2019: 216 · 2018: 245 · 2017: 273 · 2016: 317 · 2015: 299 · 2014: 296 · 2013: 349 · 2012: 351
- FWCI
- 18.71
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- ORCA Online Research @Cardiff (Cardiff University) (submittedVersion)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Pathology and Forensic Medicine › Breast Lesions and Carcinomas
- Health Sciences › Medicine › Obstetrics and Gynecology › Endometrial and Cervical Cancer Treatments
- Keywords
- early breast cancer, locoregional recurrence, breast cancer mortality, radiotherapy, breast-conserving surgery, mastectomy, axillary clearance, extent of surgery, 15-year survival, breast-conserving radiotherapy, axillary radiotherapy, adjuvant therapy, node-negative breast cancer, node-positive breast cancer, overall survival
- MeSH terms
- Aged, Breast Neoplasms, Cause of Death, Female, Humans, Middle Aged, Neoplasm Recurrence, Local, Probability, Time Factors, Randomized Controlled Trials as Topic, Disease-Free Survival
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. https://app.cochat.ai/papers/10.1016/s0140-6736(05)67887-7
- The paper
- Clarke, M. J. (2005). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. The Lancet. https://doi.org/10.1016/s0140-6736(05)67887-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.